LIFECORE BIOMEDICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.26 USD | -2.95% |
|
-3.52% | +1.78% |
| Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
| Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
Financials (USD)
| Sales 2024 * | 126M | Sales 2025 * | 145M | Capitalization | 197M |
|---|---|---|---|---|---|
| Net income 2024 * | 6M | Net income 2025 * | 18M | EV / Sales 2024 * | 1.56 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.36 x |
| P/E ratio 2024 * |
29.3
x | P/E ratio 2025 * |
11.1
x | Employees | 459 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lifecore Biomedical, Inc.
More recommendations
More press releases
More news
| 1 day | +2.70% | ||
| 1 week | -1.22% | ||
| Current month | +21.66% | ||
| 1 month | +24.47% | ||
| 3 months | -1.07% | ||
| 6 months | -11.02% | ||
| Current year | +4.36% |
1 week
6.01
6.75
1 month
4.996.75
Current year
4.508.90
1 year
4.0611.46
3 years
1.5212.88
5 years
1.5212.88
10 years
1.5215.60
| Managers | Title | Age | Since |
|---|---|---|---|
James Hall
CEO | Chief Executive Officer | 61 | 17-05-31 |
John Morberg
DFI | Director of Finance/CFO | 60 | 21-01-17 |
Steve Laninga
COO | Chief Operating Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nelson Obus
BRD | Director/Board Member | 77 | 18-10-11 |
Jeffrey Edwards
BRD | Director/Board Member | 64 | 20-10-13 |
Katrina Houde
BRD | Director/Board Member | 66 | 19-08-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +5.94% | - | |
| 0.00% | 147 M€ | +5.02% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 6.3 | -2.33% | 55 242 |
| 24-04-23 | 6.45 | +2.54% | 136,987 |
| 24-04-22 | 6.29 | -5.98% | 169,821 |
| 24-04-19 | 6.69 | +5.94% | 170,604 |
| 24-04-18 | 6.315 | -3.29% | 149,567 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.45
USD
Average target price
6
USD
Spread / Average Target
-6.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.36% | 197M | |
| +27.92% | 672B | |
| +26.57% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.47% | 217B | |
| -9.12% | 204B | |
| +6.16% | 199B | |
| -8.58% | 149B |
- Stock Market
- Equities
- LFCR Stock
